Editing Trifluoperazine (section)

== Medical uses ==
===Schizophrenia===
Trifluoperazine is an effective [[antipsychotic]] for people with schizophrenia condition.<ref name=Koc2014/> There is low-quality evidence that trifluoperazine increases the chance of being improved when compared to placebo when people are followed up for 19 weeks.<ref name=Koc2014/> There is low-quality evidence that trifluoperazine reduces the risk of relapse when compared with placebo when people are followed for 5 months.<ref name=Koc2014/> As of 2014 there was no good evidence for a difference between trifluoperazine and [[placebo]] with respect to the risk of experiencing intensified symptoms over a 16-week period nor in reducing significant agitation or distress.<ref name=Koc2014>{{cite journal | vauthors = Koch K, Mansi K, Haynes E, Adams CE, Sampson S, Furtado VA | title = Trifluoperazine versus placebo for schizophrenia | journal = The Cochrane Database of Systematic Reviews | volume = 1 | issue = 1 | pages = CD010226 | date = January 2014 | pmid = 24414883 | pmc = 6718209 | doi = 10.1002/14651858.CD010226.pub2 }} {{slink|Wikiversity:Trifluoperazine_versus_placebo_for_schizophrenia|References}}</ref>

There is no good evidence that trifluoperazine is more effective for schizophrenia than lower-potency antipsychotics like [[chlorpromazine]], [[chlorprothixene]], [[thioridazine]] and [[levomepromazine]], but trifluoperazine appears to cause more adverse effects than these drugs.<ref>{{cite journal | vauthors = Tardy M, Dold M, Engel RR, Leucht S | title = Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia | journal = The Cochrane Database of Systematic Reviews | issue = 7 | pages = CD009396 | date = July 2014 | pmid = 25003310 | doi = 10.1002/14651858.CD009396.pub2 | pmc = 11227318 }}</ref>

===Other===
It appears to be effective for people with [[generalized anxiety disorder]] but the benefit{{endash}}risk ratio was unclear as of 2005.<ref>{{cite journal | vauthors = Baldwin DS, Polkinghorn C | title = Evidence-based pharmacotherapy of Generalized Anxiety Disorder | journal = The International Journal of Neuropsychopharmacology | volume = 8 | issue = 2 | pages = 293–302 | date = June 2005 | pmid = 15576000 | doi = 10.1017/S1461145704004870 | doi-access = free }}</ref>

It has been experimentally used as a drug to kill [[eukaryotic]] [[pathogens]] such as ''[[Balamuthia]]'' in humans.<ref name="DeetzSawyer2003">{{cite journal | vauthors = Deetz TR, Sawyer MH, Billman G, Schuster FL, Visvesvara GS | title = Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases | journal = Clinical Infectious Diseases | volume = 37 | issue = 10 | pages = 1304–1312 | date = November 2003 | pmid = 14583863 | doi = 10.1086/379020 | doi-access = free }}</ref>